

Struggling to find Aklief at your pharmacy? Learn why this acne cream is hard to find in 2026 and what you can do to get your prescription filled.
You finally got a prescription for Aklief — and then your pharmacy tells you they don't have it. Sound familiar? You're not alone. Many patients across the country have run into the same frustrating problem: their pharmacy either doesn't carry Aklief or can't get it in stock quickly.
The good news is that Aklief isn't technically in a drug shortage. The real reasons it's hard to find are a bit more complicated — and once you understand them, you'll know exactly what to do next.
Aklief (Trifarotene) is a prescription topical retinoid cream used to treat acne vulgaris in patients 9 years of age and older. It was approved by the FDA in October 2019 and is made by Galderma Laboratories.
What makes Aklief unique is that it's the first new retinoid molecule developed for acne in over 20 years. Unlike older retinoids like Tretinoin or Adapalene, Aklief selectively targets retinoic acid receptor gamma (RAR-γ), the most common receptor found in skin. This makes it effective for treating acne not just on the face, but also on the chest, shoulders, and back.
For a deeper dive into how this medication works, check out our guide on how Aklief works.
As of 2026, there is no generic version of Aklief available. The patents on Trifarotene extend through 2031 to 2033, which means a cheaper generic won't hit the market for several more years. Because it's brand-name only, the retail price is high — typically $760 to over $1,000 for a single 45g pump. Many pharmacies are reluctant to stock expensive medications that may sit on the shelf.
Unlike common acne treatments such as Adapalene (Differin) or generic Tretinoin, Aklief is a specialty dermatology product. Large chain pharmacies may not keep it in their regular inventory. This doesn't mean it's unavailable — it usually means the pharmacy needs to place a special order with their distributor, which can take 1 to 3 business days.
Aklief is not covered by most Medicare plans and many commercial insurance plans. When insurance doesn't cover a medication, pharmacies see less demand for it and are less likely to stock it. Some plans require prior authorization or step therapy — meaning you may need to try a less expensive retinoid like Tretinoin or Adapalene first before your insurer will approve Aklief.
At over $760 per pump without insurance, many patients simply can't afford Aklief, even with a valid prescription. This lower demand creates a cycle: fewer patients fill the prescription, so pharmacies order less, making it harder to find when someone does need it.
Don't give up on your prescription. Here are practical steps you can take:
For more detailed tips, see our article on how to find Aklief in stock near you.
If you've tried everything and still can't fill your prescription, talk to your dermatologist about alternatives. Other topical retinoids like Tretinoin, Adapalene, or Tazarotene may work for your acne. Read our full breakdown of alternatives to Aklief to see which options might be right for you.
Aklief is a highly effective acne treatment, but finding it at your local pharmacy can be a challenge. The combination of brand-name-only pricing, limited insurance coverage, and low pharmacy stocking creates real barriers for patients. The key is to be proactive: use tools like Medfinder, ask your pharmacy to order it, and take advantage of savings programs to bring down the cost.
Your skin care shouldn't be this hard. But with the right approach, you can get the medication your doctor prescribed.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.